News & Updates

Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.

In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.

A prospective cohort study has shown that in patients aged <18 years hospitalized for acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C), neurologic manifestations during the infection are common and may predispose them more to new neurocognitive or functional morbidity at discharge.

Adding pyrazinamide (PZA) to the initial tuberculosis (TB) treatment in older patients may lead to an increase in the incidence of adverse events (AEs), particularly allergic reactions, but not in-hospital mortality, length of hospital stay, or hepatotoxicity, reports a study, which used data from the Japanese Diagnosis Procedure Combination inpatient database.